Ranibizumab in Diabetic Macular Oedema – A Benefit–risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment
Abstract
Overview
Introduction: The structured Benefit–risk Action Team (BRAT) approach aims to assist healthcare decision makers in treatment
assessments. We applied BRAT to compare the benefit–risk profile of ranibizumab 0.5 mg versus laser photocoagulation for the
treatment of diabetic macular oedema (DMO). Methods: One-year data for the ranibizumab 0.5 mg pro re nata (PRN) and laser
arms of the phase III trials RESPOND (NCT01135914; n=220), RESTORE (NCT00687804; n=345), and REVEAL (NCT00989989; n=396)
were included in the analysis. The benefit measures included ≥10 letters gain/avoidance of loss in best-corrected visual acuity (BCVA),
achieving central retinal thickness (CRT) <275 μm, and 25-item Visual Function Questionnaire (VFQ-25) outcomes. The risks measures included endophthalmitis, intraocular pressure increase, hypertension, proteinuria, arterial/venous thromboembolic events and deaths. Results: Ranibizumab treatment provided significant benefits compared with laser for ≥10 letter BCVA gain at month 12 (387/1,000 versus 152/1,000 patients), CRT <275 μm at 12 months (474/1,000 versus 348/1,000 patients), and improvement of ≥6.06 on the VFQ-25 near activities subscale (325/1,000 versus 245/1,000 patients). Results for the risk measures were similar for both treatments. Conclusions: Superior clinically relevant outcomes were observed with ranibizumab 0.5 mg PRN compared with laser without compromising on safety. This analysis further supports the positive benefit–risk profile of ranibizumab 0.5 mg PRN.
Keywords
Ranibizumab, laser, diabetic macular oedema, benefit–risk profile
Article Information
Disclosure
Focke Ziemssen is consultant for Alimera, Allergan, Bayer
Healthcare, Boehringer Ingelheim, Biogen, Novartis and Roche. Cornelia
Dunger-Baldauf, Philippe Margaron and Howard Snow are employees of
Novartis Pharma AG., Basel, Switzerland. William David Strain reports
grants and personal fees from Novartis, during the conduct of the study,
personal fees from Boehringer Ingelheim, Eli-Lilly, Janssen, Pfizer and
Novo-Nordisk outside the submitted work. Alan Cruess has nothing to
declare in relation to this article.
Correspondence
Focke Ziemssen, University Eye Hospital
Tuebingen, Elfriede-Aulhorn-Str. 7, 72074 Tuebingen, Germany.
E: focke.ziemssen@med.uni-tuebingen.de
Support
The publication of this article was supported by Novartis.
Access
This article is published under the Creative Commons
Attribution Noncommercial License, which permits any non-commercial use,
distribution, adaptation and reproduction provided the original author(s) and
source are given appropriate credit.
Acknowledgements
The authors acknowledge Claire Bailey for her
significant contribution towards the design and conduct of the analysis and for
the development of this manuscript. Writing support was provided by Jennifer
Green (Green Ink Communications) and was funded by Novartis. William David
Strain would like to acknowledge the support of the National Institute for Health
Research (NIHR) Exeter Clinical Research Facility and the NIHR Biomedical
Research Centre scheme. The views expressed in this publication are those of
the author(s) and not necessarily those of the NIHR Exeter Clinical Research
Facility, the NHS, the NIHR or the Department of Health in England.
Received
2017-05-10T00:00:00
Further Resources
Trending Topic
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles exploring current developments in endocrine and metabolic care, from evolving diagnostic approaches to advances in treatment and the challenges of translating evidence into clinical practice. We begin with an editorial from Matos and colleagues, […]
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles exploring current developments in endocrine and metabolic care, from evolving diagnostic approaches to advances in treatment and the challenges ...
Diabetes mellitus, a multifactorial, chronic and progressive metabolic disorder primarily caused by elevated blood glucose levels, is a growing global health epidemic and a leading cause of adult mortality.1,2 By 2030, global diabetes prevalence is estimated to rise to 7,079 per 100,000 individuals, ...
Youth-onset type 2 diabetes is increasingly common in the USA, with incidence exceeding that of type 1 diabetes among 15–19-year-old adolescents and prevalence projected to increase by 673% by 2060.1,2 This growth is particularly worrisome due to the severity of youth-onset type 2 diabetes, which ...
In response to the increasing prevalence of obesity, the consumption of high-calorie and high-sugar foods and an unprecedented aging population, type 2 diabetes (T2D) continues to rise globally. The International Diabetes Federation reported that 589 million individuals aged 20 to 79 years had ...
Type 2 diabetes (T2D) is a progressive metabolic condition associated with obesity, cardiovascular disease and substantial morbidity and mortality.1 Despite the availability of multiple glucose-lowering therapies, a significant proportion of individuals with T2D fail to achieve recommended glycemic targets, ...
Welcome to the summer 2026 issue of touchREVIEWS in Endocrinology. In this issue, we bring together articles that reflect the evolving complexity of endocrine and metabolic disease, while highlighting the growing importance of patient-centred care, translational science and interdisciplinary management. We ...
Urinary lithogenesis processes are activated in patients with obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D). This is a relatively unfamiliar topic among endocrinologists. Beyond the epidemiological evidence accumulated over the recent years, the purpose of this paper is ...
The past century has witnessed substantial evolution in the assessment and management of type 1 diabetes (T1D), paralleling advances in our understanding of the condition and in innovation in technology. Since the ground-breaking discovery of insulin in the 1920s, T1...
Insulin resistance (IR), a hallmark of various metabolic disorders, represents a diminished responsiveness of target tissues to the actions of insulin, resulting in impaired glucose uptake, dyslipidaemia and endothelial dysfunction.1,2 Worldwide, the prevalence of IR among adults ranges from 15.5% to 46.5%.3–5 ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles that highlight both the progress and the ongoing challenges in translating pathophysiological insight into patient-centred care. We begin with ...
The growing convergence of type 2 diabetes (T2D), obesity and dementia represents a pressing public health challenge in ageing populations worldwide.1 Robust epidemiological studies and meta-analyses have consistently shown that T2D is associated with accelerated cognitive decline.1,2 Beyond statistical ...
Approximately 20–34% of hospitalized patients have a diagnosis of diabetes, while many others experience stress hyperglycaemia, both increasing the occurrence of dysglycaemia in the hospital.1 Hyperglycaemia is associated with increased infection rates and higher mortality rates. Conversely, hypoglycaemia can lead to ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
